Biomarcadores coronarios y evolución clínica alejada en pacientes con síndromes coronarios agudos sin elevación del segmento ST

Ricardo Baeza V ^[1] ; Ramón Corbalán H ^[1] ; Pablo Castro G ^[1] ; Mónica Acevedo B ^[1] ; Teresa Quiroga G ^[1] ; Paola Viviani G ^[1]
1. [1] Pontificia Universidad Católica de Chile
  
  Pontificia Universidad Católica de Chile
  
  Santiago, Chile
Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 133, Nº. 11, 2005, págs. 1285-1293
Idioma: español
Títulos paralelos:
- Coronary biomarkers and long-term clinical outcome in acute coronary syndrome without ST segment elevation
Enlaces
- Texto completo

Resumen
- The use of new biomarkers improved risk stratification for patients with acute coronary syndromes (ACS). Aim: To evaluate the relationship between multiple biomarkers and long-term clinical outcome in ACS without ST segment elevation. Patients and Methods: Consecutive patients presenting with suspected ACS were studied. On admission to the emergency room, serum was obtained to determine highly sensitive C reactive protein (hsCRP), erythrocyte sedimentation rate (ESR), lipoprotein (a) (LPa) and soluble P selectin (sPS). Clinical endpoints were mortality and a composite endpoint of major adverse cardiovascular events (MACE) including death, re-infarction, and angina. Results: Seventy patients, aged 63±13 years, 54 males, were studied. Final diagnosis was unstable angina in 71% and non-ST-segment elevation myocardial infarction in 29%. MACE and mortality rate were 17% and 5.8%, respectively. We found higher plasma levels of hsCRP, ESR and Lp(a) in patients with MACE (p=0.032, p=0.015 and p=0.010, respectively). Plasma levels of hsCRP and ESR were also higher in patients who died during the follow up (p=0.002 y p=0.045, respectively). Conclusion: Plasma levels of inflammatory markers and atherosclerosis biomarkers are associated with a worse long-term clinical outcome in ACS without ST segment elevation. The inclusion of these biomarkers in the routine blood test on admission, could improve risk stratification of patients with ACS in the future